Abstract
Highly potent and selective CYP2C19 inhibitors are not currently available. In the present study, N-3-benzyl derivatives of nirvanol and phenobarbital were synthesized, their respective (+)- and (−)-enantiomers resolved chromatographically, and inhibitor potencies determined for these compounds toward CYP2C19 and other human liver cytochromes P450 (P450s). (−)-N-3-Benzyl-phenobarbital and (+)-N-3-benzyl-nirvanol were found to be highly potent, competitive inhibitors of recombinant CYP2C19, exhibitingKi values of 79 and 250 nM, respectively, whereas their antipodes were 20- to 60-fold less potent. In human liver preparations, (−)-N-3-benzyl-phenobarbital and (+)-N-3-benzyl-nirvanol inhibited (S)-mephenytoin 4′-hydroxylase activity, a marker for native microsomal CYP2C19, with Ki values ranging from 71 to 94 nM and 210 to 280 nM, respectively. At single substrate concentrations of 0.3 μM [(−)-N-3-benzyl-phenobarbital] and 1 μM [(+)-N-3-benzyl-nirvanol] that were used to examine inhibition of a panel of cDNA-expressed P450 isoforms, neither CYP1A2, 2A6, 2C8, 2C9, 2D6, 2E1, nor 3A4 activities were decreased by greater than 16%. In contrast, CYP2C19 activity was inhibited ∼80% under these conditions. Therefore, (+)-N-3-benzyl-nirvanol and (−)-N-3-benzyl-phenobarbital represent new, highly potent and selective inhibitors of CYP2C19 that are likely to prove generally useful for screening purposes during early phases of drug metabolism studies with new chemical entities.
Footnotes
-
↵1 Present address: Department of Basic Pharmaceutical Sciences, West Virginia University, Box 9530, Morgantown, WV 26505.
-
This work was supported in part by National Institutes of Health Grant GM 32165. Portions of this research were presented previously at the 10th North American Meeting of the International Society for the Study of Xenobiotics in Indianapolis, IN, October 24–28, 2000.
- Abbreviations used are::
- P450
- cytochrome P450
- MFL
- 3-O-methylfluorescein
- CEC
- 3-cyano-7-ethoxycoumarin
- DBF
- dibenzylfluorescein
- MAMC
- 7-methoxy-4-(aminomethyl)coumarin
- MFC
- 7-methoxy-4-(trifluoromethyl)coumarin
- HPLC
- high-performance liquid chromatography
- TLC
- thin-layer chromatography
- DMSO
- dimethyl sulfoxide
- Received September 13, 2001.
- Accepted November 28, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|